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M esenchymal stem cells (MSC) are multipotent stromal cells from bone marrow and other adult tissues. MSCs are capable of differentiating into adipogenic, osteogenic, and chondrogenic lineages. 1 Transplantation of bone marrow-derived MSC has been considered a promising treatment for ischemic tissue injuries, such as myocardial infarction and hindlimb ischemia. [2] [3] [4] [5] [6] Nonetheless, the poor retention of implanted MSC in injury site greatly limits the therapeutic potential of MSC. [7] [8] [9] It is well-known that stem cells negotiate their surrounding nutritional and signaling environments and respond accordingly in functions and fates. 10 Under hypoxic/ischemic environment, oxygen-independent glycolysis becomes the critical means for cells to generate ATP. To maintain this anaerobic metabolism for long-term survival of MSC after severe and continuous hypoxia, persistent glucose supply is required. 11, 12 Glycogen is a polymer of glucose residues in cytoplasm. 13 Glycogen plays an important role in glucose metabolism and forms an energy reserve that can be quickly mobilized to meet the sudden need for energy. [14] [15] [16] Here, we used sublethal hypoxic preconditioning (HP), a promising tool for clinical practice, 17, 18 to preactivate cellular glycogenesis. We test the hypothesis that inducible glycogen storage appeases energy shortage of MSC in ischemia, thereby promoting survival of MSC and their therapeutic efficiency. Our results showed that HP regulated glycogen metabolism of MSC through phosphoinositide 3-kinase (PI3K)/AKT and hypoxia-inducible factor-1 (HIF-1)/glycogen synthase kinase-3β (GSK-3β)-mediated pathways, which in turn promoted survival of MSC and their therapeutic efficacy for ischemic injuries.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Result HP Promoted Glycogenesis in MSC via Glycogen Synthase 1
To test our hypothesis, we first evaluated cellular glycogen storage. Experimental grouping was showed in the Table. As seen in Figure 1A , all groups of MSC displayed detectable levels of glycogen using periodic acid-schiff staining. The cells with HP show more positive staining than control. Glycogen synthase 1 (GS1) small interfering RNA inhibited HP-induced glycogenesis. These observations were confirmed further by a quantitative analysis (biochemical titration) of the glycogen content ( Figure 1B) . We defined the initial glycogen amount of MSC as basal line. After incubation for 24 hours in hypoxia, MSC showed an increase in the amount of glycogen (1.81-folds over the basal value). However, such rise was inhibited by GS1 silencing. Taken together, these results indicate that hypoxia stimulates glycogen formation of MSC via GS1. We also performed a time course study to determine the kinetics of glycogen synthesis and degradation under both normoxia and ischemia. In consequence, glycogen was accumulated during HP and was later consumed in ischemia. Meanwhile, the normoxia of MSC did not affect glycogenesis, thus showing low cell viability in long-term ischemia ( Figure 1C and 1D ).
HP-Induced Glycogen Storage Promoted MSC Survival and Therapeutic Efficiency in Subsequent Ischemia
We went on to test whether glycogen storage provides an adaptive response for MSC to encounter the subsequent hypoxic/ischemic microenvironment ( Figure 2) . A volume of 10 6 MSCs were injected into the ischemic limb of mice, the retention of these cells was determined using in vivo tracking and histological analysis. Hypoxia preconditioning increased the ratio of survival MSC (green fluorescent protein signal), although these increases were significantly attenuated by GS1 silencing (Figure 2A and 2B). These in vivo cellular retention observations were determined using histological analysis ( Figure 2C and 2D) . The green fluorescent protein signal that displays in brown was stained using the horseradish peroxidase-diaminobenzidine system.
In light of the finding that glycogen storage restored MSC viability and retention, we went on to examine the effect of glycogen storage on the MSC therapeutic efficacy. During the morphological assessment of necrosis limb ( Figure 3A and 3B), we found that MSC transplantation attenuated limb necrosis, and the HP-MSC showed a more pronounced reduction in grade 2 necrosis compared with con-MSC. However, GS1 silencing effectively abolished all such improvement (with a 3-and 2-fold increase in grade 2 and grade 3 necrosis, respectively). In Doppler perfusion image assay ( Figure 3C and 3D), HP-MSC-induced perfusion recovery was inhibited significantly using GS1 silencing (day 5, 56±11% versus 22±8.8%; day 14, 83.1±7.8% versus 33±10.3%). HP-MSC also displayed a significantly improved capillary density in ischemic tissues ( Figure 3E and 3F). Negative control small interfering RNA (HP-conRNA group) did not show any significant effects. In summary, as a fuel source for energy production, glycogen storage is a key survival element to cope with the hostile microenvironment.
PI3K/AKT Regulates Glycogen Metabolism of MSC Directly and Indirectly Through HIF-1 and GSK-3β Signaling Cascade
As one of the main switches for cellular response to extracellular stimulation, PI3K/AKT signal plays a vital role in cell adaptation. We investigated the potential role of PI3K/AKT in glycogen storage using its specific inhibitor LY294002.
Using periodic acid-schiff staining and glycogen determination, large aggregates of glycogen particles were observed in MSC under hypoxic conditions ( Figure 4A and 4B) . However, inhibition of PI3K/AKT nearly abolished HP-induced glycogenesis in MSCs ( Figure 4B ). PI3K/AKT signal directly regulated glycogen phosphorylase activity ( Figure 4C ). Meanwhile, PI3K/AKT inhibition suppressed activation of HIF-1 and GSK-3β ( Figure 4D and 4E), which may further regulate glycogen metabolism of MSC indirectly. As shown in Figure 5A and 5B, HIF-1α silencing markedly inhibited glycogen accumulation (1.75±0.15 μg/μg protein versus 1.05±0.22 ng/μg protein; P<0.05). We further studied the genes which participate in glycogenesis, including glucose transporter 1, hexokinase, phosphoglucomutase 1, and GS1. Evidence from immunofluorescence (IF) indicated that these glycogenesis-related genes were upregulated in HP-MSC in a HIF-1-dependent manner, the effects of which are abolished by HIF-1α small interfering RNA silencing. These findings were confirmed by Western blot and quantitative real-time polymerase chain reaction ( Figure 5C -5E). In our Figure IV in the online-only Data Supplement, we show that inhibition of these genes may result in the failure of HP-induced glycogen accumulation. Furthermore, HP treatment induced glycogen synthesis at least in part through inhibition of GSK-3β. HP decreased GSK-3β activity and thus stimulated glycogenesis. Upregulation of GSK-3β activity via adenovirus overexpression of GSK-3β significantly inhibited HP-induced glycogenesis ( Figure 5F -5H).
Discussion
The salient findings from our present study revealed an adaptive role of glycogen prestorage in stem cells under hostile environment, suggesting the benefit of inducible metabolic adaptation strategy in stem cell therapy. Our data further demonstrated that sublethal hypoxia preconditioning activated glycogen-based metabolic adaptation via PI3K/AKT and its downstream signal molecules HIF-1 and GSK-3β to dynamically regulate cellular glycogen storage and degradation in an effort to improve MSC survival and therapy in ischemia.
Despite significant advance during the past decade, massive loss of implanted cell resulted from the postischemic hostile microenvironment remains a major obstacle for a meaningful therapeutic remedy. [19] [20] [21] Many strategies have been implemented to overcome such barrier. 6 26 promotes MSC proliferation and migration, as well as elicits paracrine regulation. 6, 27 However, its effect on stem cell metabolism, especially the metabolic adaptation under the subsequent hostile environment, is largely unknown. Although Estrada et al 28 have demonstrated that hypoxic culture activates glycolysis of MSC, several concerns still remain. The glycolysis-based energy production depends on constant glucose supply. Question remains regarding how it works when cells are transplanted into a metabolic material-deficient condition (ischemic tissue) later on? If hypoxia-activated glycolysis is terminated by glucose deficiency in ischemic tissue, how to explain the positive effect of hypoxia on cultured MSC? Is it possible for hypoxia to induce both glycolytic catabolism and energy storage in stem cell at same time? The current study was designed to answer these outstanding questions.
Considering the critical role of glucose supply on ATP production and MSC survival, 11, 29 if one can fulfill the raw material need for energy generation, at least in the acute stage, massive loss of implanted MSC may be prevented. Therefore, we hypothesize that inducible glycogen accumulation may act as the energy storage for MSC metabolic adaptation in ischemia, thereby enhancing MSC therapeutic efficacy. Glycogenesis can be activated by short hypoxic insult in cancer cells and c2c12 myoblasts. 14, 30 In present study, we demonstrated that cellular glycogen storage was induced in MSC using HP. A previous study 6 has reported that hypoxia-stimulated glycogen storage is a consequence of the incremented amount of enzyme, rather than its activation change. Therefore, glycogenesis was blocked using GS1-specific small interfering RNA, rather than the short hairpin RNA or enzyme inhibitors.
PI3K/AKT signal is a critical regulator for cellular survival in a wide range of cell types. 31 Recent studies have identified several substrates for the serine/threonine kinase AKT, suggesting that this kinase blocks cell death though regulation of gene expression involved in cell fate and metabolic flexibility. 32 HIF-1 and GSK-3β are well-known mediators downstream of AKT for hypoxic response and glycogen metabolism, respectively. In the present study, we found that PI3K/AKT signal regulated glycogen metabolism both directly and indirectly, involving downstream HIF-1 and GSK-3β signaling molecules to regulate glycogenesis-related gene expression. In addition, PI3K/AKT regulated glycogen accumulation through direct regulation of glycogen degradation enzyme (glycogen phosphorylase) activity. It is well perceived that HIF-1 regulates a functional group of genes that associated with glycogen metabolism under hypoxia. 33 Hypoxia promotes glycogen accumulation via HIF-1-induced induction of GS1. Our results further consolidated these observations. Our data showed that the HP activated a series of glycogenesis-related genes, including glucose transporter -schiff staining) . B, Glycogen quantification was the analysis using glycogen titration assay. HP-induced glycogenesis was suppressed greatly by LY294002 (n=5). C-E, PI3K/AKT directly and indirectly regulated glycogen metabolism of MSC through hypoxiainducible factor-1 (HIF-1) and glycogen synthase kinase (GSK)-3β. C, PI3K/AKT signal directly regulated glycogen phosphorylase (GP) activity in MSC during HP. PI3K/AKT signal regulated HIF-1 (D) and GSK-3 (E), which may regulate glycogen metabolism indirectly (mean±SEM; *P<0.05 vs con-MSC; #P>0.05 vs HP-MSC). Figure 5 . Hypoxia-inducible factor-1 (HIF-1) and glycogen synthase kinase (GSK)-3 regulates glycogenesis during hypoxic preconditioning (HP). Mesenchymal stem cells (MSCs) were subjected to HIF-1 small interfering RNA (siRNA) or vehicle treatment before HP, and glycogen assay was then conducted. A, Representative images of glycogen staining (using periodic acid-schiff staining). B, Glycogen quantification was analyzed using glycogen titration assay. HP-induced glycogenesis was suppressed greatly by HIF-1α specific siRNA (n=5). C, Representative images of immunofluorescence were shown. Changes of protein expression and location of glycogenesis genes were imaged using confocal microscopy. D, Representative graph of Western blot analysis displaying expression of interested proteins. GAPDH used as loading control. E, mRNA level of glycogenesis genes was analyzed by real-time polymerase chain reaction. Glycogen synthase kinase (GSK) mediate HP-induced glycogenesis. F and G, Adenovirus overexpression of GSK-3 increased GSK-3β activity and thereby inhibiting HP-induced glycogenesis. H, GSK-3β activity (mean±SEM; *P<0.05 vs con-MSC; #P>0.05 vs HP-MSC).
1, hexokinase, phosphoglucomutase 1, and GS1 ( Figure 5 ), and inhibition of each of them abolished hypoxia-induced glycogen accumulation ( Figure IV in the online-only Data Supplement). During HP, glucose uptake of MSC significantly increased, primarily in a HIF-dependent manner. HIF-1 induces the expression of glucose transporters and hexokinase, 34, 35 and thus intracellular glucose is rapidly phosphorylated to glucose-6-phosphate by hexokinase. Glucose-6-phosphate serves as the converging point for energy supply (glycolysis) and energy storage (glycogenesis). Several possible metabolic fates have been depicted for glucose-6-phosphate including synthesizing glycogen or breaking down to pyruvate in glycolysis. 33 Phosphoglucomutase 1 is the first enzyme in glycogenesis that catalyzes the conversion of glucose-6-phosphate into glucose-1-phosphate and then into UDP-glucose. GS1 finalizes glycogen synthesis. Our results showed that GSK-3β pathway was also involved in HP-induced glycogen metabolism as evidenced by PI3K/AKT-dependent suppression of GSK-3β activity to stimulate glycogen accumulation. In addition to these indirect maneuvers, our findings revealed that PI3K/AKT signal also stimulated glycogen accumulation through direct inhibition of glycogen phosphorylase (the key glycogen degradation rate-limiting enzyme; Figure 6A ). When the cells were transplanted into the ischemic environment facing the harsh nutrition deficiency, glycogen was hydrolyzed into raw material of glycolysis to maintain adequate energy supply ( Figure 6B ). We also noted an important phenomenon that HP-MSC possessed a relatively high glycolytic enzyme activity and ATP content after long-term ischemia ( Figure III in the online-only Data Supplement). This finding implies that HP not only causes glycogen accumulation but also contributes to glycogen degradation and energy transformation when cells were transplanted into ischemia.
Excessive accumulation of glycogen induces metabolic disturbance or glycogen storage disease, the condition may interrupt cellular normal function and promote cellular injury. Current data from cell survival and therapeutic functions prove that the glycogen content induced by HP is harmless. However, the current study suffers from several limitations that warrant further investigation: we used hypoxia to trigger glycogen accumulation, which is highly dependent on HIF-1 signal. In addition, many genes involved in glycogen metabolism are downstream of HIF-1. If the glycogen accumulated in normoxia MSC where HIF-1 signal may be suppress. Did it still show enhancing effects on MSC therapy?
In summary, results from our current study demonstrated that HP turns on glycogen storage and regulates its metabolism via PI3K/AKT and its downstream HIF-1 and GSK-3β signal cascades. Glycogen storage is involved in the MSC metabolic adaptation as energy storage to promote MSC survival and therapeutic efficacy for ischemia. Our findings support a novel metabolic adaptation strategy to improve MSC therapy.
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Energy deficiency-induced poor retention of implanted mesenchymal stem cell (MSC) greatly limits its therapeutic benefit. Glycogen, an energy reserve that can be quickly mobilized to meet a sudden need for energy, has not been explored as a potential contributor in the metabolic adaption of MSC under the hostile environment. This study investigated the effect of inducible glycogen storage (by hypoxic preconditioning) in MSC therapy for ischemia. Hypoxic preconditioning aroused glycogen accumulation in MSC, and this glycogen prestorage MSCs displayed better retention and limb recovery/regeneration in ischemic limb, the effect of which may be mitigated by inhibition of glycogen storage. In addition, hypoxic preconditioning promoted prestorage glycogen catabolism and ATP production in the subsequent long-term ischemia. We found that phosphoinositide 3-kinase/AKT/hypoxia-inducible factor 1α/glycogen synthase kinase-3β pathways involved in hypoxic preconditioning-regulated glycogen metabolisms. Our data indicated a vital role for glycogen storage on MSC metabolic adaptation to ischemia, suggesting that inducible metabolic adaptation of stem cells may be a novel strategy to embellish stem cell therapy under ischemia.
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